Barinthus Bio's VTP-300 Shows Promise in Achieving Functional Cure for Chronic Hepatitis B
核心洞察
Barinthus Bio (搜索) announced Phase 2b HBV003 trial results showing HBsAg loss in eight participants treated with VTP-300 and low-dose nivolumab.
Two participants met the criteria for functional cure, demonstrating the potential of VTP-300 in chronic hepatitis B (搜索) treatment.
Two participants achieved HBsAb seroconversion after discontinuing NUC therapy, indicating a possible immune response shift.
Barinthus Bio (搜索) has announced promising results from its ongoing Phase 2b HBV003 clinical trial, evaluating VTP-300 in combination with low-dose nivolumab for the treatment of chronic hepatitis B (搜索) (CHB). The data, presented at The Liver Meeting® 2024, revealed that eight participants experienced complete HBsAg loss, with two achieving functional cure. The study (NCT05343481) includes 121 participants, 69 of whom entered with HBsAg levels below 200 IU/mL.
The HBV003 trial assesses various dosing regimens of VTP-300 alongside low-dose nivolumab, an anti-PD-1 (搜索) monoclonal antibody. Complete HBsAg loss was defined as HBsAg levels below the lower limit of quantitation. Notably, two participants who discontinued nucleoside analogue (NUC) therapy seroconverted to HBsAb positivity, suggesting a potential shift in immune response.
Potential for Functional Cure
The achievement of functional cure in two participants highlights the potential of VTP-300 as a therapeutic intervention for CHB. Functional cure, characterized by HBsAg loss and HBsAb seroconversion, is a critical goal in CHB treatment, as it signifies viral control and reduced risk of long-term complications such as cirrhosis and hepatocellular carcinoma.
VTP-300: A Novel Immunotherapeutic Approach
VTP-300 is an immunotherapeutic candidate designed to guide T cells to control disease. The combination with low-dose nivolumab aims to enhance the immune response against the hepatitis B (搜索) virus (HBV (搜索)). These results suggest that VTP-300, in conjunction with nivolumab, could offer a new strategy for managing chronic HBV infection and potentially achieving lasting remission.
The results from the HBV003 trial offer hope for improved treatment outcomes in patients with chronic hepatitis B (搜索), addressing a significant unmet medical need. Further studies are warranted to confirm these findings and to optimize the VTP-300 treatment regimen.